FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317104902> ?p ?o ?g. }

• W4317104902 endingPage "B001" @default.
• W4317104902 startingPage "B001" @default.
• W4317104902 abstract "Abstract Abstract: Sarcopenia, a condition characterized by the loss of muscle mass, strength and function with age, is highly prevalent in cancer survivors. The relationship between sarcopenia and prognosis among cancer survivors is not well understood. Methods: From the Third National Health and Nutrition Examination Survey (NHANES III), we identified 946 participants who were diagnosed with cancer (mean age 60.6 years); the most common disease sites were breast, prostate, colon and melanoma. We assembled an age, sex and race-matched cohort of 1,857 participants without cancer (mean age, 60.2 years). Sarcopenia was defined by appendicular lean mass and body height (men &lt;7.26 kg/m2, women &lt;5.45 kg/m2). Proportional-hazard models were used to assess whether sarcopenia was associated with all cause and CVD-specific time to death after taking into account baseline age, sex, race/ethnicity, smoking status, and energy intake for each cohort. In the cancer survivor cohort, models were additionally adjusted for a history of having more than one cancer and time since diagnosis. Mortality was ascertained from the National Center for Health Statistics Linked Mortality Files. Results: There were 321 deaths among cancer survivors (33.9% of the cohort) during a median follow-up of 10.5 years versus 495 deaths among participants without cancer (26.7% of the cohort) during a median follow-up of 10.9 years. Deaths from cardiovascular disease (CVD) were observed in 58 (6.1%) cancer survivors versus 122 (6.6%) participants without cancer. Overall, sarcopenia was more prevalent among cancer survivors versus the matched cohort (22.2% versus 19.7% respectively). Rates of CVD death were more than twice higher among cancer survivors with versus without sarcopenia (adjusted hazard ratio, 2.17, 95% confidence interval [CI], 1.16 to 4.05). All-cause mortality was 79% higher (adjusted hazard ratio, 1.79; 95% CI, 1.36 to 2.36) among cancer survivors with versus without sarcopenia. No significant associations were seen between sarcopenia and rates of death from all causes and CVD specifically among participants without cancer. Conclusion: Cancer survivors with sarcopenia have an increased risk of all-cause and CVD-specific mortality. In contrast, sarcopenia was not a major predictor of these outcomes in the matched cohort without cancer. Citation Format: Dejana Braithwaite, Shama Karanth, Christiaan Leeuwenburgh, Todd M. Manini, Meghann Wheeler, Danting Yang, Livingstone Aduse-Poke, Stephen Anton, Frank Penedo, Erin M. Siegel, Jonathan D. Licht, Dongyu Zhang. Elevated all-cause and cardiovascular mortality in cancer survivors with sarcopenia [abstract]. In: Proceedings of the AACR Special Conference: Aging and Cancer; 2022 Nov 17-20; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_1):Abstract nr B001." @default.
• W4317104902 created "2023-01-18" @default.
• W4317104902 creator A5013980245 @default.
• W4317104902 creator A5014816172 @default.
• W4317104902 creator A5015135329 @default.
• W4317104902 creator A5027312403 @default.
• W4317104902 creator A5028809157 @default.
• W4317104902 creator A5033401378 @default.
• W4317104902 creator A5037439650 @default.
• W4317104902 creator A5039865368 @default.
• W4317104902 creator A5051749869 @default.
• W4317104902 creator A5065184633 @default.
• W4317104902 creator A5066579890 @default.
• W4317104902 creator A5091639266 @default.
• W4317104902 date "2023-01-15" @default.
• W4317104902 modified "2023-09-29" @default.
• W4317104902 title "Abstract B001: Elevated all-cause and cardiovascular mortality in cancer survivors with sarcopenia" @default.
• W4317104902 doi "https://doi.org/10.1158/1538-7445.agca22-b001" @default.
• W4317104902 hasPublicationYear "2023" @default.
• W4317104902 type Work @default.
• W4317104902 citedByCount "0" @default.
• W4317104902 crossrefType "journal-article" @default.
• W4317104902 hasAuthorship W4317104902A5013980245 @default.
• W4317104902 hasAuthorship W4317104902A5014816172 @default.
• W4317104902 hasAuthorship W4317104902A5015135329 @default.
• W4317104902 hasAuthorship W4317104902A5027312403 @default.
• W4317104902 hasAuthorship W4317104902A5028809157 @default.
• W4317104902 hasAuthorship W4317104902A5033401378 @default.
• W4317104902 hasAuthorship W4317104902A5037439650 @default.
• W4317104902 hasAuthorship W4317104902A5039865368 @default.
• W4317104902 hasAuthorship W4317104902A5051749869 @default.
• W4317104902 hasAuthorship W4317104902A5065184633 @default.
• W4317104902 hasAuthorship W4317104902A5066579890 @default.
• W4317104902 hasAuthorship W4317104902A5091639266 @default.
• W4317104902 hasConcept C120863210 @default.
• W4317104902 hasConcept C121608353 @default.
• W4317104902 hasConcept C126322002 @default.
• W4317104902 hasConcept C147583825 @default.
• W4317104902 hasConcept C201903717 @default.
• W4317104902 hasConcept C207103383 @default.
• W4317104902 hasConcept C2776214593 @default.
• W4317104902 hasConcept C2779134260 @default.
• W4317104902 hasConcept C2779874844 @default.
• W4317104902 hasConcept C2780192828 @default.
• W4317104902 hasConcept C2908647359 @default.
• W4317104902 hasConcept C44249647 @default.
• W4317104902 hasConcept C530470458 @default.
• W4317104902 hasConcept C71924100 @default.
• W4317104902 hasConcept C72563966 @default.
• W4317104902 hasConcept C74909509 @default.
• W4317104902 hasConcept C99454951 @default.
• W4317104902 hasConceptScore W4317104902C120863210 @default.
• W4317104902 hasConceptScore W4317104902C121608353 @default.
• W4317104902 hasConceptScore W4317104902C126322002 @default.
• W4317104902 hasConceptScore W4317104902C147583825 @default.
• W4317104902 hasConceptScore W4317104902C201903717 @default.
• W4317104902 hasConceptScore W4317104902C207103383 @default.
• W4317104902 hasConceptScore W4317104902C2776214593 @default.
• W4317104902 hasConceptScore W4317104902C2779134260 @default.
• W4317104902 hasConceptScore W4317104902C2779874844 @default.
• W4317104902 hasConceptScore W4317104902C2780192828 @default.
• W4317104902 hasConceptScore W4317104902C2908647359 @default.
• W4317104902 hasConceptScore W4317104902C44249647 @default.
• W4317104902 hasConceptScore W4317104902C530470458 @default.
• W4317104902 hasConceptScore W4317104902C71924100 @default.
• W4317104902 hasConceptScore W4317104902C72563966 @default.
• W4317104902 hasConceptScore W4317104902C74909509 @default.
• W4317104902 hasConceptScore W4317104902C99454951 @default.
• W4317104902 hasIssue "2_Supplement_1" @default.
• W4317104902 hasLocation W43171049021 @default.
• W4317104902 hasOpenAccess W4317104902 @default.
• W4317104902 hasPrimaryLocation W43171049021 @default.
• W4317104902 hasRelatedWork W1444047467 @default.
• W4317104902 hasRelatedWork W1501117811 @default.
• W4317104902 hasRelatedWork W1899936169 @default.
• W4317104902 hasRelatedWork W2562234346 @default.
• W4317104902 hasRelatedWork W2742402967 @default.
• W4317104902 hasRelatedWork W2769725033 @default.
• W4317104902 hasRelatedWork W3044751778 @default.
• W4317104902 hasRelatedWork W4240851546 @default.
• W4317104902 hasRelatedWork W4317104902 @default.
• W4317104902 hasRelatedWork W4367311189 @default.
• W4317104902 hasVolume "83" @default.
• W4317104902 isParatext "false" @default.
• W4317104902 isRetracted "false" @default.
• W4317104902 workType "article" @default.